timothy sykes logo
Helius Medical Technologies Surge: What’s Driving the Spike? Thumbnail
G Google News

Helius Medical Technologies Surge: What’s Driving the Spike?

TIM SYKES•UPDATED JUN. 6, 2025, 9:18 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Helius Medical Technologies Inc. stocks have been trading up by 14.9 percent after promising medical device advancements.

Key Developments Impacting HSDT:

  • The recent study results for Helius Medical Technologies’ PoNS device provide promising news, showing sustained effectiveness in reducing gait and balance issues in multiple sclerosis patients.

  • A second major healthcare provider, United Healthcare, has approved reimbursement for the PoNS Device. This approval represents an important monetary decision of $18,100, which could influence market sentiment and institutional reception.

  • Helius announced a public offering priced at approximately $9.1M, involving 2,768,600 shares of Class A common stock warrants. Expected closing is June 6, 2025, with Maxim Group LLC as the sole placement agent.

Candlestick Chart

Live Update At 09:18:21 EST: On Friday, June 06, 2025 Helius Medical Technologies Inc. stock [NASDAQ: HSDT] is trending up by 14.9%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Overview of Helius Medical Technologies’ Financial Performance:

As traders, it’s important to remember that wealth and success in trading are not built overnight. Focusing on quick wins and short-term gains can often lead to disappointment. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” In the world of trading, patience and persistence are key. By concentrating on steady, incremental gains, traders can cultivate a wealth of experience and achievement over time, leading to more enduring success.

Helius Medical Technologies has shown consistent activity in both the innovative research and financial sectors. The PoNS device research indicates potential for a consistent revenue stream from the medical community, while also allowing the company to expand its outreach.

Financial metrics, albeit perplexing with significant variability, provide insight into the company’s strategic direction. The balance sheet suggests stabilizing cash flows, yet profitability has remained elusive with significant challenges. The recent announcement to raise funds shows active efforts to stabilize financial standing.

Reading through the company’s key ratios, it is evident that profitability margins and returns illustrate the struggle. A negative EBIT margin highlights the challenges of operating profitability. However, the current ratio of 1.7 reflects a moderate level of liquidity, indicating the capability to meet short-term financial obligations.

More Breaking News

The financial report for Q1 2025 revealed a cash flow focus with substantial movements in operating and financing activities. Strategic issuance of stock suggests that the management is looking toward longer-term growth potential rather than immediate profitability. The balance sheet prominently lists assets over liabilities, yet the company faces negative net income, which echoes the difficulty in operating successfully in the competitive medical device market.

Impact of Recent News on Market Movements:

The market chewing taken with the new study outcome announcement creates ripples throughout investor circles. Showing the PoNS device’s promise supports the company image and aids in drawing institutional interest. However, market reactions cake icing on top as they bond with tangible outcomes, such as expanding its collaboration within the healthcare industry.

The crucial moment came when United Healthcare approved reimbursement for the PoNS device. Not only is this financially significant, making treatments more accessible, but it also signifies confidence in the technology. With reimbursement approvals only recently springing up, the story conveys themes of financial and social acceptance, offering bright days for Helius Medical Technologies.

Details about the public stock offering add another layer of financial strategy calibration. By pricing the offering attractively, the company looks to bring additional capital into operations, aiming for sustained technological advancement.

What the Future Holds for HSDT:

When piecing together these recent developments, we comprehend an intricate pattern. Helius seems on a manifesto for holism through connections, teamwork, and monetary backing – all aiming for a common tune that bridges care and innovation.

Importantly, the stock appears buoyed by these events, leading some market participants to eye further shifts. The terebinth of potential operational boosts, bolstered by increased recognition, may provide impetus for ongoing stock value strengthening.

As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This axiom resonates with Helius’s current trajectory, where incremental advancements are key to fostering long-term growth and success.

In essence, Helius Medical Technologies captures tales woven with elements – a cocktail of research, financial strategy, and partnership which may foster resilience against market vicissitudes. While challenges remain, much antediluvian understanding finds itself challenged, indicating exciting potentials in burgeoning strategies.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”